{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:13:02Z","timestamp":1761894782106},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,10,7]],"date-time":"2008-10-07T00:00:00Z","timestamp":1223337600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1007\/s12185-008-0176-2","type":"journal-article","created":{"date-parts":[[2008,10,6]],"date-time":"2008-10-06T04:00:59Z","timestamp":1223265659000},"page":"434-440","source":"Crossref","is-referenced-by-count":13,"title":["Epstein\u2013Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma"],"prefix":"10.1007","volume":"88","author":[{"given":"Katja C.","family":"Weisel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eckhart","family":"Weidmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Anagnostopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lothar","family":"Kanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Pezzutto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,7]]},"reference":[{"key":"176_CR1","first-page":"267","volume":"7","author":"S Louie","year":"1980","unstructured":"Louie S, Daoust PR, Schwartz RS. Immunodeficiency and the pathogenesis of non-Hodgkin\u2019s lymphoma. Semin Oncol. 1980;7:267\u201384.","journal-title":"Semin Oncol."},{"issue":"Suppl2","key":"176_CR2","doi-asserted-by":"publisher","first-page":"S254","DOI":"10.1097\/01.tp.0000186382.81130.ba","volume":"80","author":"JF Buell","year":"2005","unstructured":"Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation. 2005;80(Suppl2):S254\u201364. doi: 10.1097\/01.tp.0000186382.81130.ba .","journal-title":"Transplantation"},{"key":"176_CR3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1146\/annurev.immunol.15.1.405","volume":"15","author":"AB Rickinson","year":"1997","unstructured":"Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Ebstein\u2013Barr virus infection. Annu Rev Immunol. 1997;15:405\u201331. doi: 10.1146\/annurev.immunol.15.1.405 .","journal-title":"Annu Rev Immunol."},{"key":"176_CR4","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1002\/1097-0142(19871115)60:10<2412::AID-CNCR2820601010>3.0.CO;2-F","volume":"60","author":"G Pizzolo","year":"1987","unstructured":"Pizzolo G, Vinante F, Agostini C, Zambello R, Trentin L, Masciarelli M, et al. Immunologic abnormalities in angioimmunoblastic lymphadenopathy. Cancer. 1987;60:2412\u20138. doi:10.1002\/1097-0142(19871115)60:10<2412::AID-CNCR2820601010>3.0.CO;2-F.","journal-title":"Cancer."},{"key":"176_CR5","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1309\/6UTX-GVC0-12ND-JJEU","volume":"117","author":"A Zettl","year":"2002","unstructured":"Zettl A, Lee SS, R\u00fcdiger T, Starostik P, Marino M, Kirchner T, et al. Ebstein\u2013Barr virus-associated B-cell lymphoproliferative disorders in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified. M J Clin Pathol. 2002;117:368\u201379. doi: 10.1309\/6UTX-GVC0-12ND-JJEU .","journal-title":"M J Clin Pathol."},{"key":"176_CR6","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1182\/blood.V80.7.1804.1804","volume":"80","author":"I Anagnostopoulos","year":"1992","unstructured":"Anagnostopoulos I, Hummel M, Finn T, Tiemann M, Korbjuhn P, Dimmler C, et al. Heterogenous Ebstein\u2013Barr virus infection patterns in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type. Blood. 1992;80:1804\u201312.","journal-title":"Blood."},{"key":"176_CR7","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1182\/blood.V79.7.1789.1789","volume":"79","author":"LM Weiss","year":"1992","unstructured":"Weiss LM, Jaffe ES, Liu XF, Chen YY, Shibata D, Medeiros LJ. Detection and localization of Ebstein\u2013Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. Blood. 1992;79:1789\u201395.","journal-title":"Blood."},{"key":"176_CR8","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/j.1365-2141.2007.06725.x","volume":"138","author":"K Willenbrock","year":"2007","unstructured":"Willenbrock K, Brauninger A, Hansmann ML. Frequent occurrence of B-cell lymphomas in angioummunoblastic T-cell lymphoma and proliferation of Ebstein\u2013Barr virus-infected cells in early cases. Br J Haematol. 2007;138:733\u20139. doi: 10.1111\/j.1365-2141.2007.06725.x .","journal-title":"Br J Haematol."},{"key":"176_CR9","doi-asserted-by":"publisher","first-page":"364","DOI":"10.7326\/0003-4819-117-5-364","volume":"117","author":"W Siegert","year":"1992","unstructured":"Siegert W, Agthe A, Griesser H, Schwedtfeger R, Brittinger G, Engelhard M, et al. Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM\/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group. Ann Intern Med. 1992;117:364\u201370.","journal-title":"Ann Intern Med."},{"key":"176_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1086\/504811","volume":"43","author":"SI Martin","year":"2006","unstructured":"Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis. 2006;43:16\u201324. doi: 10.1086\/504811 .","journal-title":"Clin Infect Dis."},{"issue":"2","key":"176_CR11","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1053\/j.seminhematol.2005.12.010","volume":"43Suppl 2","author":"R Kurzrock","year":"2006","unstructured":"Kurzrock R, Ravandi F. Purine analogues in advanced T-cell lymphoid malignancies. Semin Hematol. 2006;43Suppl 2(2):S27\u201334. doi: 10.1053\/j.seminhematol.2005.12.010 .","journal-title":"Semin Hematol"},{"key":"176_CR12","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1182\/blood-2003-04-1044","volume":"102","author":"N Yawalkar","year":"2003","unstructured":"Yawalkar N, Ferenczi K, Jones DA, Yamanaka K, Suh KY, Sadat S, et al. Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma. Blood. 2003;102:4059\u201366. doi: 10.1182\/blood-2003-04-1044 .","journal-title":"Blood."},{"key":"176_CR13","doi-asserted-by":"publisher","first-page":"5748","DOI":"10.1158\/1078-0432.CCR-04-2514","volume":"11","author":"K Yamanaka","year":"2005","unstructured":"Yamanaka K, Yawalkar N, Jones DA, Hurwitz D, Ferenczi K, Eapen S, et al. Decreased T-cell receptor excision circles in cutaneous T-cell lymphoma. Clin Cancer Res. 2005;11:5748\u201355. doi: 10.1158\/1078-0432.CCR-04-2514 .","journal-title":"Clin Cancer Res."},{"key":"176_CR14","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1309\/6UTX-GVC0-12ND-JJEU","volume":"117","author":"A Zettl","year":"2002","unstructured":"Zettl A, Lee SL, R\u00fcdiger T, Starostik P, Marino M, Kirchner T, et al. Ebstein\u2013Barr virus-associated B-cell lymphoproliferative disorders in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified. Am J Clin Pathol. 2002;117:368\u201379. doi: 10.1309\/6UTX-GVC0-12ND-JJEU .","journal-title":"Am J Clin Pathol."},{"key":"176_CR15","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.5858\/2006-130-1707-ATLWSE","volume":"130","author":"RC Hawley","year":"2006","unstructured":"Hawley RC, Cankovic M, Zarbo RJ. Angioimmunoblastic T-cell lymphoma with supervening Ebstein\u2013Barr virus-Associated Large B-cell Lymphoma. Arch Pathol Lab Med. 2006;130:1707\u201311.","journal-title":"Arch Pathol Lab Med."},{"key":"176_CR16","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/0145-2126(91)90468-9","volume":"15","author":"K Tobinai","year":"1991","unstructured":"Tobinai K, Ohtsu T, Hayashi M, Kinoshita T, Matsuno Y, Mukai K, et al. Ebstein\u2013Barr virus (EBV) genome carrying monoclonal B-cell lymphoma in a patient with adult T-cell leukaemia-lymphoma. Leuk Res. 1991;15:837\u201346. doi: 10.1016\/0145-2126(91)90468-9 .","journal-title":"Leuk Res."},{"key":"176_CR17","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/j.1365-2559.2004.01997.x","volume":"46","author":"F Luzzatto","year":"2005","unstructured":"Luzzatto F, Pruneri G, Benini E, Manzotti M, Laszlo D, Martinelli G, et al. Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centers and a high content of EBV-infected large B-cells carrying IgH chain gene monoclonal rearrangement. Histopathology. 2005;46:464\u20136. doi: 10.1111\/j.1365-2559.2004.01997.x .","journal-title":"Histopathology."},{"key":"176_CR18","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1182\/blood-2002-01-0159","volume":"100","author":"J Lundin","year":"2002","unstructured":"Lundin J, Kimby E, Bjoerkholm M, Broliden PA, Celsing F, Hjalmar V, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukaemia (B-CLL). Blood. 2002;100:768\u201373. doi: 10.1182\/blood-2002-01-0159 .","journal-title":"Blood."},{"key":"176_CR19","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","volume":"99","author":"MJ Keating","year":"2002","unstructured":"Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99:3554\u201361. doi: 10.1182\/blood.V99.10.3554 .","journal-title":"Blood."},{"key":"176_CR20","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1182\/blood.V98.6.1721","volume":"98","author":"CE Dearden","year":"2001","unstructured":"Dearden CE, Matutes E, Cazin B, Tjonnfjord GE, Parreira A, Nomdedeu B, et al. High remission rate in T-cell prolymphocytic leukaemia with CAMPATH-1H. Blood. 2001;98:1721\u20136. doi: 10.1182\/blood.V98.6.1721 .","journal-title":"Blood."},{"key":"176_CR21","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","volume":"101","author":"J Lundin","year":"2003","unstructured":"Lundin J, Hagberg H, Repp R, Cavallin-Stahl E, Freden S, Juliusson G, et al. Phase 2 study of alemtuzumab (anti-CD52 antibody) in patients with advanced mycosis fungoides\/Szezary syndrome. Blood. 2003;101:4267\u201372. doi: 10.1182\/blood-2002-09-2802 .","journal-title":"Blood."},{"key":"176_CR22","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","volume":"103","author":"G Enblad","year":"2004","unstructured":"Enblad G, Hagberg H, Erlanson M, Porwit Lundin J, MacDonald A, Repp R, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy refractory peripheral T-cell lymphomas. Blood. 2004;103:2920\u20134. doi: 10.1182\/blood-2003-10-3389 .","journal-title":"Blood."},{"key":"176_CR23","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/sj.leu.2403258","volume":"18","author":"J Lundin","year":"2004","unstructured":"Lundin J, Porwit-McDonald A, Rossmann ED, Karlsson C, Edman P, Rezvany MR, et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia. 2004;18:484\u201390. doi: 10.1038\/sj.leu.2403258 .","journal-title":"Leukemia."},{"key":"176_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3816\/CLM.2002.n.016","volume":"3","author":"DD Nguyen","year":"2002","unstructured":"Nguyen DD, Cao TM, Dugan K, Starcher SA, Fechter RL, Coutre SE. Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukaemia and prolymphocytic leukaemia. Clin Lymphoma. 2002;3:105\u201310.","journal-title":"Clin Lymphoma."},{"key":"176_CR25","first-page":"1248","volume":"89","author":"L Laurenti","year":"2004","unstructured":"Laurenti L, Piccioni P, Cattani P, Cingolani A, Efremov D, Chiusolo P, et al. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukaemia.: incidence and treatment with oral ganciclovir. Haematologica. 2004;89:1248\u201352.","journal-title":"Haematologica."},{"key":"176_CR26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1365-2141.2005.05570.x","volume":"130","author":"DS Gibbs","year":"2005","unstructured":"Gibbs DS, Westerman D, McCormack C, Sexymour JF, Prince HM. Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders. Br J Haematol. 2005;130:87\u201391. doi: 10.1111\/j.1365-2141.2005.05570.x .","journal-title":"Br J Haematol."},{"key":"176_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2005.05789.x","volume":"132","author":"KA Thursky","year":"2005","unstructured":"Thursky KA, Worth LJ, Seymour JF, Prince HM, Slavin MA. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol. 2005;132:3\u201312. doi: 10.1111\/j.1365-2141.2005.05789.x .","journal-title":"Br J Haematol."},{"key":"176_CR28","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.3324\/haematol.12465","volume":"93","author":"A Nosari","year":"2008","unstructured":"Nosari A, Tedeschi A, Ricci F, Montillo M. Characteristics and stage of the underlying diseases could determine the risk of opportunistic infections in patients receiving alemtuzumab. Haematologica. 2008;93:e30\u20131 (online only).","journal-title":"Haematologica"},{"key":"176_CR29","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1086\/510388","volume":"44","author":"AY Peleg","year":"2007","unstructured":"Peleg AY, Husain S, Kwak EJ, Silveira FP, Ndirangu M, Tran J, et al. Opportunistic Infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD52 antibody. Clin Infect Dis. 2007;44:204\u201312. doi: 10.1086\/510388 .","journal-title":"Clin Infect Dis."},{"key":"176_CR30","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1200\/JCO.2002.06.119","volume":"20","author":"KR Rai","year":"2002","unstructured":"Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, et al. Alemtuzumab in previously treated chronic lymphocytic leukaemia patients who also had received fludarabine. J Clin Oncol. 2002;20:3891\u20137. doi: 10.1200\/JCO.2002.06.119 .","journal-title":"J Clin Oncol."},{"key":"176_CR31","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJM200312253492622","volume":"349","author":"IM Ghobrial","year":"2003","unstructured":"Ghobrial IM, Otteman LA. An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab. N Engl J Med. 2003;349:2570\u20131. doi: 10.1056\/NEJM200312253492622 .","journal-title":"N Engl J Med."},{"key":"176_CR32","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.trim.2006.10.006","volume":"17","author":"K Sebelin-Wulf","year":"2007","unstructured":"Sebelin-Wulf K, Nguyen TD, Oertel S, Papp-Vary M, Trappe RU, Schulzki A, et al. Quantitative analysis of EBV-specific CD4\/CD8 T cell numbers, absolute CD4\/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD. Transpl Immunol. 2007;17:203\u201310. doi: 10.1016\/j.trim.2006.10.006 .","journal-title":"Transpl Immunol."},{"key":"176_CR33","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1111\/j.1600-6143.2007.01972.x","volume":"7","author":"AD Kirk","year":"2007","unstructured":"Kirk AD, Cherikh WS, Ring M, Burke G, Kaufman D, Knechtle SJ, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant. 2007;7:2619\u201325. doi: 10.1111\/j.1600-6143.2007.01972.x .","journal-title":"Am J Transplant."},{"key":"176_CR34","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1097\/00000478-200205000-00009","volume":"26","author":"LV Abruzzo","year":"2002","unstructured":"Abruzzo LV, Rosales CM, Medeiros LJ, Vega F, Luthra R, Manning JT, et al. Ebstein\u2013Barr virus-positive lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. Am J Surg Pathol. 2002;26:630\u20136. doi: 10.1097\/00000478-200205000-00009 .","journal-title":"Am J Surg Pathol."},{"issue":"Suppl1","key":"176_CR35","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1023\/A:1008372814223","volume":"11","author":"N Milpied","year":"2000","unstructured":"Milpied N, Vasseur B, Parquet N, Garnier JL, Antoine C, Quartier P, et al. Humanized anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol. 2000;11(Suppl1):113\u20136. doi: 10.1023\/A:1008372814223 .","journal-title":"Ann Oncol"},{"key":"176_CR36","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1182\/blood.V95.4.1502.004k40_1502_1505","volume":"95","author":"I Kuehnle","year":"2000","unstructured":"Kuehnle I, Huls MH, Liu Z, Semmelmann M, Krance RA, Brenner MK, et al. CD20 monoclonal antibody (rituximab) for therapy of Ebstein\u2013Barr virus lymphoma after hematopoietic stem-cell transplantation. Blood. 2000;95:1502\u20135.","journal-title":"Blood."},{"key":"176_CR37","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1182\/blood-2003-12-4287","volume":"103","author":"HJ Wagner","year":"2004","unstructured":"Wagner HJ, Cheng YC, Huls MH, Gee AP, Kuehnle I, Krance RA, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood. 2004;103:3979\u201381. doi: 10.1182\/blood-2003-12-4287 .","journal-title":"Blood."},{"key":"176_CR38","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1111\/j.1600-6143.2007.01823.x","volume":"7","author":"P Comoli","year":"2007","unstructured":"Comoli P, Basso S, Zecca M, Pagliara D, Baldanti F, Bernardo ME, et al. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant. 2007;7:1648\u201355. doi: 10.1111\/j.1600-6143.2007.01823.x .","journal-title":"Am J Transplant."},{"key":"176_CR39","doi-asserted-by":"crossref","unstructured":"Kluin-Nelemans HC, Coenen JL, Boers JE, van Imhoff GW, Rosati S. EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Blood. 2008 (epub ahead of print).","DOI":"10.1182\/blood-2008-02-138800"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-008-0176-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-008-0176-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-008-0176-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-008-0176-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T20:34:31Z","timestamp":1631910871000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-008-0176-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,7]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["176"],"URL":"https:\/\/doi.org\/10.1007\/s12185-008-0176-2","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,7]]}}}